Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. reports developments as a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Recurring updates cover its chronic hepatitis delta program, including the investigational combination of tobevibart and elebsiran, and its oncology portfolio of PRO-XTEN® dual-masked T-cell engagers across solid tumor targets.
Company news also includes clinical data presentations, trial progress, financial results, equity financing activity, and strategic collaborations. Its VIR-5500 program is a PSMA-targeted PRO-XTEN® dual-masked T-cell engager for metastatic prostate cancer, and the company also describes preclinical work across infectious diseases and oncologic malignancies.
Vir Biotechnology (Nasdaq: VIR) reported updated Phase 1 dose-escalation results for VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager in metastatic castration-resistant prostate cancer (mCRPC).
In 58 monotherapy patients there were no dose-limiting toxicities, manageable Grade ≥3 treatment-related adverse events in 12% (7/58), dose-dependent anti-tumor activity in ≥3,000 µg/kg cohorts (PSA50 82%, PSA90 53%) and RECIST objective responses of 45% (5/11); registrational trial planned for 2027.
Vir Biotechnology (Nasdaq: VIR) and Astellas (TSE: 4503) entered a global collaboration to co-develop and co-commercialize VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager for prostate cancer.
Vir will receive $335M upfront/near-term, share U.S. profits 50/50, and may receive up to $1.37B additional milestones; Astellas leads U.S. commercialization and holds ex-U.S. exclusive rights. Global development costs split 60/40 (Astellas/Vir). Closing is subject to customary conditions including HSR clearance.
Vir Biotechnology (Nasdaq: VIR) will host a conference call on Monday, February 23, 2026 at 5:30 p.m. ET / 2:30 p.m. PT to provide a corporate update and discuss fourth-quarter and full-year financial results for the period ended December 31, 2025.
According to the company, the call can be accessed via the Events & Presentations page on Vir Biotechnology's website.
Vir Biotechnology (Nasdaq: VIR) reported positive Phase 2 SOLSTICE results in chronic hepatitis delta showing undetectable HDV RNA (TND) in 88% of combination tobevibart + elebsiran participants evaluated at Week 96 versus 46% with antibody monotherapy at Week 96. No treatment-related Grade ≥3 adverse events were observed in the combination arm. The registrational ECLIPSE program is fully enrolled (ECLIPSE 1 and 3) with ECLIPSE 1 topline expected in Q4 2026 and ECLIPSE 2/3 toplines in Q1 2027. Vir will present Phase 1 VIR-5500 data at ASCO GU 2026. Year-end cash and investments were ~$781M, with runway into Q4 2027 after the Norgine licensing agreement.
Vir Biotechnology (NASDAQ: VIR) announced that CEO Marianne De Backer will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:45 p.m. PT in San Francisco.
A live webcast will be available under Events & Presentations in the company's Investors section and the webcast will be archived for 30 days.
Vir Biotechnology (NASDAQ: VIR) granted Norgine an exclusive commercial license for the combination of tobevibart + elebsiran to treat chronic hepatitis delta in Europe, Australia and New Zealand.
Key terms: an initial reimbursement payment of EUR 55 million, up to EUR 495 million in milestones, tiered mid‑teen to high‑twenties percent royalties, and shared ECLIPSE program costs with Norgine funding ~25% of go‑forward external costs. Vir retains U.S. and other non‑Greater China rights.
Corporate and clinical updates: ECLIPSE 3 enrollment completed; Vir expects existing cash, cash equivalents and investments to extend into Q4 2027 under the current plan. Prior Phase 2 SOLSTICE data showed 66% (21/32) achieved HDV RNA target not detected with the combination and no grade 3+ treatment‑related adverse events.
Vir Biotechnology (Nasdaq: VIR) announced that CEO Marianne De Backer will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida.
A live webcast will be available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.
Vir Biotechnology (Nasdaq: VIR) reported Week 48 Phase 2 SOLSTICE results showing the monthly combination of tobevibart + elebsiran achieved 66% HDV RNA target not detected (21/32) and ~90% HBsAg <10 IU/mL. ALT normalized in 56% at Week 48. The regimen was well tolerated with no grade 3+ treatment-related adverse events and no treatment-related discontinuations. Data were presented at AASLD The Liver Meeting® and published in the New England Journal of Medicine. Vir’s registrational ECLIPSE program is underway with topline results from ECLIPSE 1–3 expected in Q1 2027. The program holds FDA Breakthrough and Fast Track and EMA PRIME and orphan designations.
Vir Biotechnology (Nasdaq: VIR) announced that CEO Marianne De Backer will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18, 2025 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London.
A live webcast will be available via the company's Investors & Events page and the presentation will be archived online for 30 days.
Vir Biotechnology (NASDAQ: VIR) reported Q3 2025 results and a corporate update on November 5, 2025. The company ended the quarter with $810.7 million in cash, cash equivalents and investments and expects runway into mid-2027. Clinical highlights include ECLIPSE 1 enrollment completing ~two months ahead of schedule with primary completion expected in Q4 2026 and topline data for ECLIPSE 1–3 expected in Q1 2027. VIR-5500 first patient dosed in an ARPI combination study and a comprehensive VIR-5500 data update is planned for Q1 2026. Q3 financials: revenue $0.2M, R&D $151.5M, SG&A $22.2M, and net loss $163.1M ($1.17/share). A conference call was held November 5, 2025.